An update of Scandinavian studies of osteosarcoma

  • Inkeri Elomaa
Part of the Cancer Treatment and Research book series (CTAR, volume 62)

Abstract

The total population of all Scandinavian countries is about 22 million. These countries have a similar social structure, a modern medical service covering all inhabitants, and an effective registration system for all cancer patients. Based on these similarities, the Scandinavian Sarcoma Group (SSG) was founded in 1979 with the intention of improving the prognosis for patients with sarcoma. In the first study period 1982–1989, a nonrandomized trial based on Rosen’s T10 protocol [1] for patients with operable osteosarcoma was used. Preliminary results have been published [2], and the complete data are currently under analysis. The second study, started in April 1990 and is based on the results and experience obtained from the preceding protocol and recent reports from other centres. This article gives an update of both trials. In addition, the Finnish 10-year results of osteosarcoma treatment are reviewed [3].

Keywords

Toxicity Oncol Sarcoma Doxorubicin Methotrexate 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of primary tumor to preoperative chemotherapy. Cancer 49:1221–1230, 1982.PubMedCrossRefGoogle Scholar
  2. 2.
    Solheim Ö, Alvegård TA, Elomaa I. Adjuvant chemotherapy for osteosarcoma. A preliminary report from the Scandinavian Sarcoma Group. Acta Oncol 28(Suppl 2):53–57, 1989.Google Scholar
  3. 3.
    Elomaa I, Siimes M, Blomqvist C, et al. Ten years’ experience in patients with osteogenic sarcoma in Finland. Eur J Surg Oncol 16:147–152, 1990.PubMedGoogle Scholar
  4. 4.
    Rosen G, Marcove RG, Caparros B, et al. Primary osteogenic sarcoma. The rationale for preoperative chemotherapy and delayed surgery. Cancer 43:2163–2177, 1979.PubMedCrossRefGoogle Scholar
  5. 5.
    Siimes MA, Elomaa I, Koskimies A. Testicular function after chemotherapy for osteosarcoma. Eur J Cancer 26:973–975, 1990.PubMedCrossRefGoogle Scholar
  6. 6.
    Saeter G, Alvergård TA, Elomaa I, Solheim Ö. Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single agent high-dose methotrexate. A Scandinavian Sarcoma Group Study. Clin Oncol 9:1766–1775, 1991.Google Scholar
  7. 7.
    Winkler K. COSS-86. Kooperative osteosarkomstudie. Therapie-protokoll. Gesellschaft für pädiatrische Oncologic, Hamburg, 1987.Google Scholar
  8. 8.
    Weiner MA, Harris MB, Lewis M, et al. Neoadjuvant high-dose methotrexate, cisplatin and doxorubicin, for management of patients with nonmetastatic osteosarcoma. Cancer Treat Rep 70:1431–1432, 1986.PubMedGoogle Scholar
  9. 9.
    Zalupski M, Baker LH. Ifosfamide. J Natl Cancer Inst 80:556–566, 1988.PubMedCrossRefGoogle Scholar
  10. 10.
    Scandinavian Sarcoma Group. The treatment of osteosarcoma. Trial protocol of SSG VIII, prepared by the Working Committee of the SSG. SSG Secretariat, Oncologic Center Lund, Sweden.Google Scholar
  11. 11.
    Meistrich ML, Chawla CP, Da Cunha MF, et al. Recovery of sperm production after chemotherapy for osteosarcoma. Cancer 63:2115–2123, 1989.PubMedCrossRefGoogle Scholar
  12. 12.
    Friend SH, Bernands RR. A human DNA segment with properties of the gene that predisposes to retinobastoma and osteosarcoma. Nature 323:646–664, 1986.CrossRefGoogle Scholar
  13. 13.
    Hiddeman W, Rosner A, Wormann B, et al. Tumor heterogenity in osteosarcoma as identified by flow cytometry. Cancer 59:324–328, 1987.CrossRefGoogle Scholar
  14. 14.
    Mandahl N, Rydholm A. Cytogenetic abnormalities in tumors of bone and soft tissues. Acta Oncol 28(Suppl 2):69–73.Google Scholar
  15. 15.
    Karaharju E, Knuutila S, Elomaa I. Chromosome study in bone tumors. Acta Scand Traumt Orthoped 61:235, 1990.Google Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • Inkeri Elomaa
    • 1
  1. 1.Department of Radiotherapy and OncologyUniversity of HelsinkiHelsinkiFinland

Personalised recommendations